RecruitingNot Applicable

EmboTrap ® II Revascularization Device (Neuravi) in Acute Ischemic Stroke

Italy100 participantsStarted 2022-01-01

Plain-language summary

The primary aim of Registrap study is to assess the safety and effectiveness of the EmboTrap®II Clot Retriever device (Neuravi) in patients with acute ischemic stroke from large vessel occlusion.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria * Signed Informed Consent Form * Large Vessel Occlusion on CTA or MRA in the Anterior or Posterior Proximal Cerebral Vasculature up to A1, M1, Dominant M2, P1 * ASPECTS ≥ 6 * Mismatch or good collaterals showed at MR or multiphasic CTA or pCT * Groin Puncture performed within 12 hours from symptom onset * Use of EmboTrap® II Revascularization Device (Neuravi) as the first or second line treatment Exclusion criteria * Informed consent not given * Extracranial or tandem occlusion

What they're measuring

Safety: device -related haemorrhages rate showed by CT/MR

Timeframe: 10 days

Efficacy: Restoration of cerebral blood flow at the end of the procedure

Timeframe: 1 day

Trial details

NCT IDNCT03601702

SponsorNiguarda Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-12-31

Contact for this trial

Edoardo Boccardi, MD

00396444 edoardo.bocccardi@ospedaleniguarda.it

View on ClinicalTrials.gov More Acute Ischemic Stroke trials